Skip to main content

Advertisement

SpringerLink
Log in

Reply to: appropriate dosing of burosumab in tumor-induced osteomalacia

  • Letter to the Editor
  • Published:
Osteoporosis International Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 01 December 2022

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jan de Beur SM, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, Rauch F, Luca D, Cimms T, Roberts MS, San Martin J, Carpenter TO (2021) Burosumab for the treatment of tumor-induced osteomalacia. J Bone Miner Res 36(4):627–635. https://doi.org/10.1002/jbmr.4233

    Article  CAS  Google Scholar 

  2. Imanishi Y, Ito N, Rhee Y, Takeuchi Y, Shin CS, Takahashi Y, Onuma H, Kojima M, Kanematsu M, Kanda H, Seino Y, Fukumoto S (2021) Interim analysis of a phase 2 open-label trial assessing Burosumab efficacy and safety in patients with tumor-induced osteomalacia. J Bone Miner Res 36(2):262–270. https://doi.org/10.1002/jbmr.4184

    Article  CAS  Google Scholar 

  3. Crotti C, Bartoli F, Coletto LA, Manara M, Marini E, Daolio PA, Parafioriti A, Armiraglio E, Zucchi F, Sinigaglia L, Caporali R, Varenna M (2021) Tumor induced osteomalacia: a single center experience on 17 patients. Bone 152:116077. https://doi.org/10.1016/j.bone.2021.116077

    Article  CAS  Google Scholar 

  4. Xiao L, Homer-Bouthiette C, Hurley MM (2018) FGF23 neutralizing antibody partially improves bone mineralization defect of HMWFGF2 isoforms in transgenic female mice. J Bone Miner Res 33(7):1347–1361. https://doi.org/10.1002/jbmr.3417

    Article  CAS  Google Scholar 

  5. Bansal S, Khazim K, Suri R, Martin D, Werner S, Fanti P (2016) Tumor induced osteomalacia: associated with elevated circulating levels of fibroblast growth factor-7 in addition to fibroblast growth factor-23. Clin Nephrol 85(1):57–62. https://doi.org/10.5414/CN108596

    Article  CAS  Google Scholar 

  6. Tajima S, Fukayama M (2015) Fibroblast growth factor receptor 1 (FGFR1) expression in phosphaturic mesenchymal tumors. Int J Clin Exp Pathol 8(8):9422–9427

    Google Scholar 

  7. Amblee A, Uy J, Senseng C, Hart P (2014) Tumor-induced osteomalacia with normal systemic fibroblast growth factor-23 level. Clin Kidney J 7(2):186–189. https://doi.org/10.1093/ckj/sfu004

    Article  CAS  Google Scholar 

  8. Toyosawa S, Tomita Y, Kishino M, Hashimoto J, Ueda T, Tsujimura T, Aozasa K, Ijuhin N, Komori T (2004) Expression of dentin matrix protein 1 in tumors causing oncogenic osteomalacia. Mod Pathol 17(5):573–578. https://doi.org/10.1038/modpathol.3800084

    Article  CAS  Google Scholar 

  9. Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, Oudet CL (2000) MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67(1):54–68. https://doi.org/10.1006/geno.2000.6235

    Article  CAS  Google Scholar 

  10. Crotti C, Zucchi F, Alfieri C, Caporali R, Varenna M (2022) Long-term use of burosumab for the treatment of tumor-induced osteomalacia. Osteoporos Int. https://doi.org/10.1007/s00198-022-06516-6

    Article  Google Scholar 

  11. Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L (2017) Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs 31(4):299–316. https://doi.org/10.1007/s40259-017-0231-8

    Article  CAS  Google Scholar 

  12. Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, Pavelka K, Mahgoub E, Kotak S, Korth-Bradley J, Pedersen R, Mele L, Shen Q, Vlahos B (2017) Correction: the impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. Plos One 12(6):e0179308. https://doi.org/10.1371/journal.pone.0179308

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, ASST-Pini-CTO, Milan, Italy

    C. Crotti, F. Zucchi, R. Caporali & M. Varenna

  2. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

    C. Alfieri & R. Caporali

  3. Department of Nephrology, Dialysis and Renal Transplant, Foundation Ca’ Granda IRCCS Ospedale Maggiore Policlinico, Milan, Italy

    C. Alfieri

Authors
  1. C. Crotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Zucchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Alfieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Caporali
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Varenna
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Varenna.

Ethics declarations

Conflict of interest

Massimo Varenna has received advisory board honoraria from Kyowa Kirin. Chiara Crotti has received speaker honoraria from Kyowa Kirin. All other authors have no conflicts of interest to declare.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Crotti, C., Zucchi, F., Alfieri, C. et al. Reply to: appropriate dosing of burosumab in tumor-induced osteomalacia. Osteoporos Int 34, 423–424 (2023). https://doi.org/10.1007/s00198-022-06618-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-022-06618-1

Search

Navigation